SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 74 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $481,000 | -46.0% | 27,664 | -66.0% | 0.00% | -72.7% |
| Q1 2020 | $891,000 | -0.4% | 81,248 | -20.3% | 0.01% | +22.2% |
| Q4 2019 | $895,000 | +50.2% | 101,952 | +27.8% | 0.01% | +28.6% |
| Q3 2019 | $596,000 | +100.0% | 79,744 | +149.0% | 0.01% | +75.0% |
| Q2 2019 | $298,000 | +250.6% | 32,032 | +97.7% | 0.00% | +300.0% |
| Q1 2019 | $85,000 | -55.5% | 16,200 | -62.3% | 0.00% | -66.7% |
| Q4 2018 | $191,000 | -63.0% | 42,939 | -32.8% | 0.00% | -57.1% |
| Q3 2018 | $516,000 | +79.8% | 63,915 | +56.6% | 0.01% | +40.0% |
| Q2 2018 | $287,000 | – | 40,815 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |